Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.

Abstract

Introduction: The therapeutic options for mantle cell lymphoma (MCL) include traditional chemo-immunotherapy for newly diagnosed cases, and targeted treatments including the bruton tyrosine kinase inhibitors in the relapsed/refractory (R/R) disease setting. The advent of commercially available chimeric antigen receptor (CAR) T-cell therapy in the last three years has dramatically improved the outcomes of patients with R/R large B-cell lymphoma.Areas covered: This review is an in-depth evaluation and appraisal of brexucabtagene autoleucel (brexu-cel), the first anti-CD19 CAR T-cell therapy to be approved for patients with R/R MCL, after the results of a Phase II (ZUMA-2) trial.Expert opinion: In the absence of head-to-head comparison studies with Btk inhibitors, up-front use of brexu-cel in patients with high-risk MCL and poor prognostic features may be advantageous, possibly even before exposure to Btk inhibitor, and further study of this approach is warranted. While data on long-term outcomes of CAR T-cell therapy in MCL patients are needed, brexu-cel has shown remarkable clinical activity and its regulatory approval has immediate practice-changing implications in this highly aggressive malignancy.

• Authors: Agrima Mian, Brian T Hill
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 21 Issue 4 Pg. 435-441 (04 2021) ISSN: 1744-7682 [Electronic] England
• PMID: 33566715 (Publication Type: Journal Article, Review)

Chemical References

• Antigens, CD19
• Protein Kinase Inhibitors

Topics

• Adult
• Antigens, CD19
• Humans
• Immunotherapy, Adoptive
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Mantle-Cell (drug therapy)
• Protein Kinase Inhibitors (adverse effects)